Glow in the dark fluid:Nanoparticles and DNA-binding antibodies as priming agents for liquid biopsies

照亮黑液的光芒:纳米颗粒和DNA结合抗体作为引发剂助力液体活检

Current challenges and opportunities for liquid biopsies.Liquid biopsies serve as an indispensable clinical diagnostic tool when traditional biopsies are difficult to obtain or yield inadequate samples for genetic monitoring.However,achieving optimal sensitivity and stability poses a significant challenge due to the difficulty of detecting low levels of plasmatic cell-free DNA(cfDNA).Recently,Dr.Carmen Martin-Alonso and colleagues[1]reported that priming agents,consisting of nanoparticles and DNA-binding monoclonal antibodies(mAbs),could significantly improve the sensitivity and robustness of liquid biopsies.The innovative use of priming agents promises improved liquid biopsies across various clinical applications by enhancing efficacy,accuracy,and depth of ex vivo sequencing and analysis.Importantly,it reduces the need to draw large blood volumes from patients or perform extensive plasma exchange to obtain sufficient cfDNA(Table 1).